In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Endocyte (ECYT). The company’s shares opened today at $23.65, close to its 52-week high of $23.89.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.6% and a 43.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Endocyte has an analyst consensus of Moderate Buy.
See today’s analyst top recommended stocks >>
Based on Endocyte’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.61 million. In comparison, last year the company had a GAAP net loss of $23.27 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.
